Table: Anges - 6-MTH group results
Aug 8 (Reuters)-
Anges, Inc.
CONSOLIDATED FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
6 months ended 6 months ended Year to
Jun 30, 2025 Jun 30, 2024 Dec 31, 2025
LATEST YEAR-AGO LATEST
RESULTS RESULTS FORECAST
Sales 414 mln 347 mln 1.35
(+19.4 pct) (+578.5 pct) (+109.7 pct)
Operating loss 2.40 loss 5.11 loss 5.80
Recurring loss 3.90 loss 3.19 loss 5.82
Net loss 3.97 loss 3.50 loss 5.85
EPS loss 12.07 yen loss 16.60 yen loss 17.04 yen
Ann Div NIL NIL
-Q2 div NIL NIL
-Q4 div NIL NIL
NOTE - Anges, Inc..
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4563.T
Recent news on AnGes
See all newsTable: Anges -Q1 group results
Brief: Vasomune Therapeutics, Inc., And Anges, Inc., Announce Us FDA Clearance Of Investigational New Drug (Ind) Application For Pegevongitide (Av-001) Treatment In Resuscitation Of Severely Burned Patients
Table: Anges -2025 parent results
Table: Anges -2025 group results
Brief: Anges & Vasomune Therapeutics Enter Agreement For AV-001